Frederick Beddingfield III, MD, PhD is CEO of Sienna Biopharmaceuticals, Inc, a company focused on developing breakthrough products in aesthetics and dermatology. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in October 2015.

Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, and LATISSE®, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss.

Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.

Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Ascendis Pharma A/S (NASDAQ: ASND), ProNAi Therapeutics (NASDAQ: DNAI), Carbylan Therapeutics (NASDAQ: CBYL), AirXpanders (ASX: AXP), and several private companies. He was an investor in Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG).

Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.

John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $1B in assets under management.

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad spectrum of product development functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™. Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of Zoomi, Inc., is currently a member of the board of directors for Zoomi, Inc. and for Brickell Biotech, Inc., is a trustee of the Morristown Medical Center Foundation, and serves on the Advisory Council for the Keller Center of entrepreneurship at Princeton University.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.

Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.

In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.

Hans-Jörg Bergler joined Merz in 2007 as Head of Corporate Development. In 2014, he assumed responsibility for Global Corporate Development, HR and Communications.

During his time at Merz, the company has pursued an effective growth and realignment strategy and today is focused specifically on aesthetic medicine and neurotoxins. Over the past four years, Mr. Bergler played a critical role in the acquisitions of Ulthera, Anteis, Neocutis and OnLight Sciences, as well as in the creation of the Merz Corporate Venture Capital Initiative.

Mr. Bergler has 20 years of experience in corporate strategic planning and M&A positions in Germany and the USA. Prior to joining Merz, he worked at Altana Pharma AG and Boehringer Ingelheim GmbH and was in charge of M&A, leading numerous strategic projects. Mr. Bergler is a German national and he holds a degree in Business Administration from Munich University in Germany.

Michael Brinkman is a Managing Director in the Global Healthcare Investment Banking Group at Jefferies. He focuses on U.S. Biotechnology and Specialty Pharmaceutical companies. Mr. Brinkman has been one of the most active bankers in the Biotechnology industry during his 23-year investment banking career. Prior to joining Jefferies, he was a Managing Director at Piper Jaffray for two years, and head of biotechnology investment banking at CIBC World Markets where he spent 14 years. Before that Mr. Brinkman worked as an actuary in life and health insurance companies in the U.S. and South Africa. He graduated magna cum laude with a BS degree from the University of the Witwatersrand in South Africa and his Fellowship from the Faculty of Actuaries in Edinburgh, Scotland. Michael’s recent Dermatology clients includes, Aclaris, Anacor and Foamix.

As Sr. Vice President, Medical Dermatology for Allergan, Jag is responsible for the commercialization and pipeline development of this business in the United States. Prior to this role, Jag has led the Managed Markets and Government Affairs functions and the Global Strategic Marketing function developing the strategy and delivery of the pipeline within the pharmaceutical and device portfolios across the Allergan Aesthetics and Dermatology business.

Prior to joining Allergan, Jag worked at GlaxoSmithKline for over 15 years in several executive commercial roles in both Europe and the United States. Jag holds a BA (Hons) degree in Business Studies from Sheffield in the UK.

Peter Nicholson has worked in healthcare for over 30 years and is responsible for the worldwide strategy and business development functions at Nestle Skin Health, whose mission is to deliver science-based solutions for the skin, hair and nails. He was co-creator of the Nestlé Skin Health SHIELD initiative, focused on the convergence of technology and cross-discipline collaboration to develop new insights that advance patient care. He is a member of the European Institute of Innovation & Technology - Health C.A.R.E. program, the American Academy of Dermatology and the European Academy of Dermatology and Venereology.

Peter has a Bachelor’s degree in biochemistry with an emphasis on immunology from the University of California at Berkeley, where he pursued post-graduate research in the lab of Dr. Robert I. Mishell. He has a Master’s degree in Business Administration from the Anderson School of Business at UCLA. He was co-founder and CEO of Blue Heron Biotechnology which developed an automated and highly-accurate gene synthesis platform for the production of genes and gene variants for use in expression analysis. Peter has volunteered as a mentor and coach for the Cartier Women's Initiative awards and served as a judge for the MassChallenge Switzerland business accelerator program.

Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline’s Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.

N. Nicole Stakleff is a partner with Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney since 2002, Ms. Stakleff concentrates her practice in intellectual property law, including strategic patent prosecution and counseling and due diligence in the pharmaceutical, chemical, medical and other life sciences fields.